Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, March 2000, p. 561-567, Vol. 44, No. 3
Department of Microbiology, Kitasato
University School of Medicine, 1-15-1 Kitasato, Sagamihara,
Kanagawa 228-8555, Japan
Received 26 August 1999/Returned for modification 12 November
1999/Accepted 8 December 1999
The ampC and ampR genes of
Enterobacter cloacae GN7471 were cloned into pMW218 to
yield pKU403. Four mutant plasmids derived from pKU403 (pKU404, pKU405,
pKU406, and pKU407) were isolated in an AmpD mutant of
Escherichia coli ML4953 by selection with ceftazidime or
aztreonam. The Chromosomal class C AmpD is a novel N-acetylmuramyl-L-alanine
amidase that participates in the intercellular recycling of
peptidoglycan fragments (11, 15). AmpD degrades cytoplasmic
1,6-anhydro-N-acetylmuramyl-tripeptide (1,6-anhMurNAc-tripeptide) to release the tripeptide
L-Ala-D-Glu-meso-diaminopimelic acid
(meso-DAP) for direct utilization in the construction of new
peptidoglycans (15, 16). An ampD mutation that
results in In the present study, we selected mutant strains by culture with an
expanded-spectrum cephalosporin and a monobactam and examined the
genetic background of ampC and ampR mutations
that conferred high levels of resistance to Bacterial strains and plasmids.
The bacterial strains and
plasmids used in this study are listed in Table
1. pACYC184 and pMW218 are vector
plasmids that confer resistance to tetracycline-chloramphenicol and
kanamycin, respectively, and were purchased from Nippon Gene (Tokyo,
Japan) (5). pMW218 was derived from pSC101 (3).
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
ampR Gene Mutations That Greatly
Increase Class C
-Lactamase Activity in Enterobacter
cloacae
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-lactamase activities expressed by pKU404, pKU405,
pKU406, and pKU407 were about 450, 75, 160, and 160 times higher,
respectively, than that expressed by the original plasmid, pKU403.
These mutant plasmids all carried point mutations in the
ampR gene. In pKU404 and pKU405, Asp-135 was changed to Asn
and Val, respectively. In both pKU406 and pKU407, Arg-86 was changed to
Cys. The ease of selection of AmpR mutations at a frequency of about
10
6 in this study strongly suggests that derepressed
strains, such as AmpD or AmpR mutants, could frequently emerge in the
clinical setting.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-lactamase is
an inducible enzyme produced by Enterobacter cloacae and
many other gram-negative bacilli (4, 14, 17, 29, 31, 38).
The AmpD, AmpG, and AmpR proteins are reported to be involved in the
induction of class C
-lactamase (32, 33, 35).
-lactamase expression even in the absence of a
-lactamase inducer coincides with the accumulation of
1,6-anhMurNAc-tripeptide (15). Inactivation of AmpD leads to
semiconstitutive or hyperinducible overproduction of AmpC in
Citrobacter freundii and E. cloacae (8, 19,
21). On the other hand, AmpD mutants with increased levels of
-lactamase expression show one of three phenotypes (hyperinducible,
derepressed, and partially derepressed), which are associated with
different mutations or which may depend on environmental regulation of
unknown genes (40). AmpG is a transmembrane protein
involved in the permease for an N-acetylglucosaminyl
(GluNAc)-1,6-anhMurNAc-tripeptide (15, 25). Dietz et al.
(7) have reported that AmpG primarily affects
aD-pentapeptide (disaccharide-pentapeptide;
GluNAc-1,6-anhMurNAc-L-Ala-D-Glu-meso-DAP-D-Ala-D-Ala), a periplasmic muropeptide that is converted into the cytoplasmic signaling molecule for
-lactamase induction, aM-pentapeptide (monosaccharide-pentapeptide;
L1,6-anhMurNAc-L-Ala-D-Glu-meso-DAP-D-Ala-D-Ala) (7). Without ampG, neither induction nor
high-level expression of
-lactamase is possible (20).
AmpR acts as a transcriptional activator by binding to a DNA region
immediately upstream of the ampC promoter (2, 12,
24). In the absence of a
-lactam inducer, AmpR represses the
synthesis of
-lactamase by 2.5-fold, whereas expression is induced
10- to 200-fold in the presence of a
-lactam inducer (22,
23). On the other hand, many clinical isolates of the family
Enterobacteriaceae show high-level production of class C
-lactamase even without induction.
-lactam antibiotics, as
well as compared the enzyme activity with that of the parental strain. The possible mechanisms by which these mutant strains had a strong response to an expanded-spectrum cephalosporin and a monobactam are discussed.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Bacterial strains and plasmids used in this study
Antibiotics. Reference samples of various antibiotics of known potency were kindly supplied in powder form by the respective manufacturers, as follows: ampicillin, Meiji Seika (Tokyo, Japan); cephaloridine, Shionogi (Osaka, Japan); cefotaxime, Nippon Hoechst Marion Roussel (Tokyo, Japan); cefotiam, Takeda Chemical Industries (Osaka, Japan); ceftazidime, Nippon Glaxo (Tokyo, Japan); aztreonam, Eisai (Tokyo, Japan); latamoxef, Shionogi; cefpodoxime, Sankyo (Tokyo, Japan); imipenem, Banyu Pharmaceutical (Tokyo, Japan); cefepime, Bristol-Myers Squibb K. K. (Tokyo, Japan); and kanamycin, Meiji Seika.
Determination of antibiotic sensitivity. The MICs of the antibiotics were determined by the agar dilution method. Briefly, an overnight culture in Muller-Hinton broth (Nissui, Tokyo, Japan) was diluted to about 5 × 107 CFU/ml and was inoculated onto agar plates containing various concentrations of the test antibiotic by using an inoculating device which applied spots of bacterial suspensions containing 5 × 104 CFU.
Transformation of Escherichia coli. Plasmid DNAs were isolated and were used to transform E. coli ML4947 (AmpD wild type) and ML4953 (AmpD mutant), as well as E. cloacae ATCC 13047 and clinical isolates of E. cloacae, by electroporation (6, 34, 37).
Cloning of ampC and ampR genes.
Genomic DNA was purified by the procedure of Marmur (28).
Plasmid DNA was purified by extracting plasmid DNA by the small-scale alkaline method (37). Restriction enzymes and T4 DNA ligase were purchased from Takara shuzo (Kyoto, Japan) and Nippon Gene, respectively. The plasmid size was calculated from the sizes of the
fragments obtained by cleaving the plasmid with restriction enzymes and
by using
phage DNA cleaved with HindIII as a
molecular marker. PCR primers were obtained from Amersham Pharmacia
Biotech (Tokyo, Japan). PCR was carried out according to the
instructions with the GeneAmp PCR reagent kit (Perkin-Elmer Cetus,
Emeryville, Calif.). All PCRs were performed on a Perkin-Elmer Cetus
DNA thermal cycler (model 480) (34, 36).
|
Assay of
-lactamase activity.
-Lactamase activity was
detected as described previously (34). Briefly, imipenem (a
carbapenem), a
-lactamase inducer, was added to
mid-logarithmic-phase cultures and the cells were incubated for another
2 h. Imipenem was added at several concentrations (1/4× the MIC
of imipenem) so that the cell protein concentration was not less than
75% compared with that for the controls. Cell lysis was negligible
under these conditions, allowing enzyme activity to be assessed. The
cells were harvested by centrifugation (1,700 × g, 10 min), resuspended in 3 ml of 50 mM potassium phosphate buffer (pH 7.0),
and sonicated. After centrifugation at 14,000 × g for
10 min at 4°C, the
-lactamase activity and the protein concentration in the extract were measured and were compared between cultures. One unit of
-lactamase activity was defined as the amount
of
-lactamase that hydrolyzed 1 µmol of cephalothin in 1 min at
30°C.
Isolation of ceftazidime- or aztreonam-resistant mutants. Mutants with elevated levels of resistance to ceftazidime or aztreonam were obtained by plating about 109 CFU/ml of washed late-logarithmic-phase ML4953/pKU403 grown in L broth on agar plates containing ceftazidime or aztreonam at 4× to 16× the MIC.
DNA sequencing. Analysis of the ampC and ampR sequences of pKU403 was performed as described by Sanger et al. (39). The DNA sequences of the ampR genes carried by pKU404, pKU405, pKU406, and pKU407 were determined with an ALFred DNA sequencer (Amersham Pharmacia Biotech) and the Thermo Sequenase fluorescence-labeled primer sequencing kit (Amersham Pharmacia Biotech). Sequencing primers were obtained from Amersham Pharmacia Biotech. The sequencing primers for the ampR gene, CY5AP4, CY5AR1 CY5AR2, and CY5AR3, were designed from the sequence of ampR (GenBank accession no. AB016612). Forward primers CY5AR1 (5'-CCCAGGAGAAGCTAAAAGTGG-3') and CY5AR3 (5'-GATGGTCTTTGATTCGTCCGTG-3') are located at nucleotides 352 to 372 and nucleotides 722 to 743, respectively, on the sequence, while reverse primers CY5AP4 (5'-TGCGTAAAACTGAGGTGTCTGGCG-3') and CY5AR2 (5'-TAGGAGCGCAGCAGGGTAAACT-3') are located at nucleotides 151 to 128 and 652 to 631, respectively.
Nucleotide sequence accession numbers. The nucleotide sequence data reported in this paper will appear in the DDBJ, EMBL, and GenBank nucleotide sequence databases with the accession nos. AB016611 (ampC) and AB016612 (ampR).
| |
RESULTS |
|---|
|
|
|---|
Base sequences of ampC and ampR from E. cloacae GN7471. The 8-kb DNA fragment from an EcoRI digest of E. cloacae GN7471 containing the ampC and ampR genes was introduced into the EcoRI site of pACYC184. The resulting plasmid, designated pMS161, was digested with SalI and was ligated into pMW218 at the SalI site, and the plasmid thus obtained was named pKU403. In this case, the DNA fragment was 6 kb in length. Next, the base sequence of pKU403 was determined. The degree of identity of ampC between E. cloacae GN7471 and E. cloacae MHN1 was 81.8%, while that between E. cloacae GN7471 and E. cloacae P99 was 81.8%. However, the degree of identity of ampC between E. cloacae P99 and MHN1 was 98.3% (10). In contrast, the degree of identity of ampR between DNA derived from E. cloacae GN7471 and that derived from E. cloacae MHN1 was 99.3% (12).
Isolation of mutants and MICs.
For isolation of mutants and
determination of MICs, E. coli ML4953, which carried an AmpD
mutant background, was used in order to avoid selecting only an AmpD
mutant. Mutant strains were isolated from ML4953/pKU403 by selection
with ceftazidime or aztreonam. When selection was performed with
ceftazidime at 4× to 8× the MIC (2 to 4 µg/ml), mutants were
obtained at a frequency of 6.2 × 10
6 to 2.0 × 10
6. With selection at 16× the MIC (8 µg/ml), mutants
were obtained at a frequency of 3.4 × 10
8. When
selection was performed with aztreonam at 4× to 8× the MIC (2 to 4 µg/ml), mutants were obtained at a frequency of 6.4 × 10
6 to 1.4 × 10
6, while the frequency
of occurrence of mutants was 3.8 × 10
9 at 16× the
MIC (8 µg/ml).
|
ampC or
ampR plasmids were almost the same
as the MICs for the parental strains.
-Lactamase activities of mutants.
The
-lactamase
activities encoded by the plasmids are shown in Table
3. When E. coli ML4947 (AmpD
wild type) was the host cell, the
-lactamase activities encoded by
pKU404, pKU405, pKU406, and pKU407 were about 470, 75, 160, and 180 times higher, respectively, than the activity encoded by the original
plasmid (pKU403). However, the activity of the
-lactamase encoded by
pKU403 increased about 50-fold when it was induced by imipenem, whereas
the
-lactamase activity encoded by pKU405, pKU406, and pKU407 rose
only three- to fivefold. The
-lactamase activity encoded by pKU404
was not induced by imipenem.
|
-lactamase activities encoded by pKU403, pKU404, pKU405, pKU406, and
pKU407 were much higher compared with those when E. coli
ML4947 was the host. Induction with imipenem resulted in an eightfold increase for pKU403 and a twofold increase for pKU405. However, no
increase in activity was observed for pKU404, pKU406, or pKU407. These
results indicated that pKU406 and pKU407 encoded similar levels of
-lactamase activity and had activities intermediate between those of
pKU404, which encoded a high level of enzyme activity, and pKU405,
which encoded a low level of enzyme activity. Hence, pKU404, pKU405,
and pKU406 (which encoded different levels of enzyme activity) were
used in subsequent experiments.
The specific enzyme activities encoded by
ampR plasmids
(pKU408, pKU409, pKU410, and pKU414) in E. coli ML4947 (AmpD
wild type) and ML4953 (AmpD mutant) were 0.06 to 0.16 U/mg of protein and were two to four times higher than the
-lactamase activity encoded by ML4953/pKU403 but were markedly lower than the activities encoded by pKU404, pKU405, and pKU406. Similarly, since
ampC plasmids (pKU411, pKU412, pKU413, and pKU415) lacked
the structural gene for
-lactamase, their enzyme activities were
always less than 0.02 U/mg of protein and did not differ from the
activities of the host cells.
Amino acid sequence of AmpR.
Figure
2 shows the AmpR amino acid sequences
encoded by pKU403, pKU404, pKU405, and pKU406 derived from E. cloacae GN7471, as well as those from the AmpR form of E. cloacae MHN1 and C. freundii OS60 (13, 25).
G-538 in the base sequence of pKU403 was converted to A in pKU404,
resulting in the replacement of Asp-135 by Asn. A-539 in the base
sequence of pKU403 was converted to T in pKU405, and Asp-135 was
replaced by Val. C-256 in the base sequence of pKU403 was converted to
T in both pKU406 and pKU407, with Arg-86 being replaced by Cys.
|
Effect of mutant AmpR on chromosomal
-lactamase.
In the
experiment described above no difference in enzyme activity was found
among
ampR plasmids, while the
-lactamase activities encoded by pKU404, pKU405, and pKU406 were significantly higher than
the activity of the pKU403-encoded
-lactamase. Therefore, the high
level of enzyme activity encoded by the plasmids isolated in the
present study appeared to be due to a mutation of ampR. To
confirm this,
ampC plasmids (pKU411, pKU412, pKU413, and
pKU415) were used to transform E. cloacae ATCC 13047 as well
as clinical isolates of E. cloacae (KU3261, KU3262, and
KU3263), and the effects of mutations in AmpR were examined. Table
4 shows that the
-lactamase activities
of the pKU411 transformants were almost the same as those of the host
strains, whereas the activities of the pKU412, pKU413, and pKU415
transformants were 20 to 350 times, 10 to 130 times, and 15 to 250 times higher, respectively.
|
| |
DISCUSSION |
|---|
|
|
|---|
The frequency of occurrence of mutants that stably express
derepressed class C
-lactamase in subpopulations of resistant organisms and the widespread use of
-lactams in the hospital environment have resulted in the emergence of clinically important endemic bacterial resistance (9). The differences between
individual inducible strains that cause infection remain unclear, but
these organisms appear to carry mutations in either AmpD or AmpR.
Many gram-negative bacilli (e.g., Enterobacter spp.,
C. freundii, Pseudomonas aeruginosa, and
Serratia marcescens) produce chromosomal class C
-lactamases. The ampC gene used in the present study was
derived from a clinical isolate, E. cloacae GN7471, and
showed about 80% identity with those reported in E. cloacae P99 and E. cloacae MHN1 (10). However,
microbiological comparison of E. cloacae GN7471 and E. cloacae P99 has shown that they belong to the same species
(18). That is, among bacterial strains assigned to the same
species by microbiological methods, classification into close relatives
may be possible when identification is done at the gene level.
The degree of identity of ampR between DNA derived from E. cloacae GN7471 and that derived from E. cloacae MHN1 was 99.3%. In contrast, the degree of identity of AmpR between DNA derived from E. cloacae GN7471 and C. freundii OS60 was only 73.0%. However, the AmpR amino acid sequences of Arg-86, Gly-102, and Asp-135 were conserved between E. cloacae GN7471, E. cloacae MHN1, and C. freundii OS60 (Fig. 2).
As shown in Table 2, MICs appeared to be inconsistent with
-lactamase activity (Table 3). In E. coli ML4947 (AmpD
wild type), the
-lactamase activity of pKU404 was sixfold higher
than that of pKU405. In the case of E. coli ML4953 (AmpD
mutant), the enzyme activity of pKU404 was only 1.6-fold higher than
that of pKU405. On the contrary, the
-lactamase activities encoded
by
ampR plasmids (pKU408, pKU409, pKU410, and pKU414) in
E. coli were markedly lower than the activities encoded by
pKU404, pKU405, and pKU406. This result maybe indicates that
-lactamase was induced on a plate with drug and that the mutations
in pKU404 and pKU405 are located in different sites of AmpR.
Two of the mutant plasmids obtained in the present study, pKU404 and
pKU405, had single-base mutations of ampR, resulting in
mutation of Asp-135. pKU406 and pKU407 also had only a one-base mutation, with a consequent change in Arg-86. Bartowsky and colleagues (1, 33) have reported on the variability of AmpR from
C. freundii, and they isolated AmpR with alterations of
Ser-35, Tyr-264, Gly-102, and Asp-135 by using nitrosoguanidine
mutagenesis and site-directed mutagenesis. In our study, a change of
wild-type Asp-135 to Asn (pKU404) or Val (pKU405) resulted in 470-fold
and 75-fold increases in basal levels of
-lactamase expression,
respectively, while a change of wild-type Arg-86 to Cys (pKU406 and
pKU407) resulted in 160-fold and 180-fold increases, respectively
(Table 3).
As for the mutations of Asp-135 (pKU404 and pKU405) and Arg-86 (pKU406
and pKU407), these amino acids also appear to be important for
ampC activation. A change of either the 86th or the 135th amino acid of AmpR affected the ampC promoter. In other
words, these mutants were considerably more active than wild-type AmpR as transcriptional activators for the ampC promoter. These
high levels of expression of
-lactamase were shown in the presence or absence of a
-lactam inducer and in the AmpD wild type (ML4947) or AmpD mutant (ML4953).
On the other hand, for about 3% of clinical isolates the cefotaxime
and ceftazidime MICs were less than 0.125 µg/ml, and we could not
detect any class C
-lactamase in clinical isolates of E. cloacae (data not shown). In this study, we selected three isolates of E. cloacae (KU3261, KU3262, and KU3263) with
-lactamase activities of 0.02, 0.03, and <0.02 U/mg of protein,
respectively. As shown in Table 4, the activities of pKU412, pKU413,
and pKU415 transformants (
ampR plasmids) were 20 to 350 times, 10 to 130 times, and 15 to 250 times higher, respectively.
In the present study, since mutant plasmids were selected by using AmpD
mutant strains as the host cells, the resulting mutants may also have
had mutations at sites other than ampD. On the other hand,
the frequency of selection of AmpD mutants was about 10
5
in another study (27). The frequency of occurrence of stably derepressed class C
-lactamase mutations in a bacterial population can be as high as 10
5 (26). The existence of
such mutants has serious clinical implications with regard to the
generation of AmpC-producing strains during selective therapy with
broad-spectrum
-lactams. These strains appear to carry a mutation of
either AmpD or AmpR. The selection of AmpR mutants at a frequency of
10
6 or less strongly suggests that frequent generation of
derepressed mutant strains, such as AmpD mutants, might occur first in
the clinical setting, followed by selection of AmpR mutants. In the real situation both ampR and ampD are chromosomal
single-copy genes. In these experiments, ampR is on a
multicopy plasmid. This clearly affects the mutation frequency. Hence,
it is much more likely that clinical E. cloacae isolates
resistant to
-lactamase contain ampD mutations than
ampR mutations, since any harmful event to the AmpD
basically increases the level of resistance, whereas specific
ampR mutations are needed to create an AmpR that works as an
activator even in the absence of a muropeptide inducer. The potentially
interesting aspect of this study is that an ampD mutation
may perhaps be followed by an ampR mutation, creating further resistance. The problem is that it is not known if a
single-copy version of the ampR mutants studied here
actually will increase the level of
-lactamase expression in an
ampD knockout mutant of E. cloacae. It is not
known whether replacement of a single-copy version of the mutated
ampR gene by wild-type ampR on the chromosome of
E. cloacae will actually increase the level of resistance in AmpD wild-type strains.
| |
ACKNOWLEDGMENTS |
|---|
We thank Y. Ohya for excellent technical assistance.
This work was supported by grant 09670296 (to M.I.) from the Japanese Ministry of Education and by a grant for diagnosis of antibiotic resistance from the Japanese Ministry of Health and Welfare.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan. Phone: 81-427-78-9355. Fax: 81-427-78-9350. E-mail: matsu{at}kitasato-u.ac.jp.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Bartowsky, E., and S. Normark.
1991.
Purification and mutant analysis of Citrobacter freundii AmpR, the regulator for chromosomal AmpC -lactamase.
Mol. Microbiol.
5:1715-1725[Medline].
|
| 2. | Bartowsky, E., and S. Normark. 1993. Interactions of wild-type and mutant AmpR of Citrobacter freundii with target DNA. Mol. Microbiol. 10:555-565[Medline]. |
| 3. |
Bernardi, A., and F. Bernardi.
1984.
Complete sequence of pSC101.
Nucleic Acids Res.
12:9415-9426 |
| 4. |
Bush, K.,
G. A. Jacoby, and A. A. Medeiros.
1995.
A functional classification scheme for -lactamases and its correlation with molecular structure.
Antimicrob. Agents Chemother.
39:1211-1233[Medline].
|
| 5. |
Chang, A. C. Y., and S. N. Cohen.
1978.
Construction and characterization of amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic miniplasmid.
J. Bacteriol.
134:1141-1156 |
| 6. |
Cohen, S. N.,
A. C. Chang, and L. Hsu.
1972.
Nonchromosomal antibiotic resistance in bacteria: genetic transformation of Escherichia coli by R-factor DNA.
Proc. Natl. Acad. Sci. USA
69:2110-2114 |
| 7. |
Dietz, H.,
D. Pfeifle, and B. Wiedemann.
1997.
The signal molecule for -lactamase induction in Enterobacter cloacae is the anhydromuramyl-pentapeptide.
Antimicrob. Agents Chemother.
41:2113-2120[Abstract].
|
| 8. | Ehrhardt, A. F., C. C. Sanders, J. R. Romero, and J. S. Leser. 1996. Sequencing and analysis of four new Enterobacter ampD alleles. Antimicrob. Agents Chemother. 40:1953-1956[Abstract]. |
| 9. | Fung-Tomc, J. C., E. Gradelski, E. Huczko, T. J. Dougherty, R. E. Kessler, and D. P. Bonner. 1996. Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrob. Agents Chemother. 40:1289-1293[Abstract]. |
| 10. |
Galleni, M.,
F. Lindberg,
S. Normark,
S. Cole,
N. Honore,
B. Joris, and J.-M. Frere.
1988.
Sequence and comparative analysis of three Enterobacter cloacae ampC -lactamase genes and their products.
Biochem. J.
250:753-760[Medline].
|
| 11. |
Holtje, J. V.,
U. Kopp,
A. Ursinus, and B. Wiedemann.
1994.
The negative regulator of -lactamase induction AmpD is a N-acetyl-anhydromuramyl-L-alanine amidase.
FEMS Microbiol. Lett.
122:159-164[CrossRef][Medline].
|
| 12. | Honore, N., M. H. Nicolas, and S. T. Cole. 1986. Inducible cephalosporinase production in clinical isolates of Enterobacter cloacae is controlled by a regulatory gene that has been deleted from Escherichia coli. EMBO J. 5:3709-3714[Medline]. |
| 13. | Inoue, M., J. Itoh, and S. Mitsuhashi. 1983. pMS76, a plasmid capable of amplification by treatment with chloramphenicol. Plasmid 9:86-97[CrossRef][Medline]. |
| 14. |
Jacobs, C.,
J. M. Frere, and S. Normark.
1997.
Cytosolic intermediates for cell wall biosynthesis and degradation control inducible -lactam resistance in gram-negative bacteria.
Cell
88:823-832[CrossRef][Medline].
|
| 15. |
Jacobs, C.,
L. Huang,
E. Bartowsky,
S. Normark, and J. T. Park.
1994.
Bacterial cell wall recycling provides cytosolic muropeptides as effectors for -lactamase induction.
EMBO J.
13:4684-4694[Medline].
|
| 16. |
Jacobs, C.,
B. Joris,
M. Jamin,
K. Klarsov,
J. V. Beeumen,
D. Mengin-Lecreulx,
J. V. Heijenoort,
J. T. Park,
S. Normark, and J. M. Frere.
1995.
AmpD, essential for both -lactamase regulation and cell wall recycling, is a novel cytosolic N-acetylmuramyl-L-alanine amidase.
Mol. Microbiol.
15:553-559[Medline].
|
| 17. |
Jones, R. N.,
F. Baquero,
G. Privitera,
M. Inoue, and B. Wiedemann.
1997.
Inducible -lactamase-mediated resistance to third-generation cephalosporins.
Clin. Microbiol. Infect.
3:7-20[Medline].
|
| 18. |
Joris, B.,
J. Dusart,
J.-M. Frere,
J. V. Beeumen,
E. L. Emanuel,
S. Petursson,
J. Gagnon, and S. G. Waley.
1984.
The active site of the P99 -lactamase from Enterobacter cloacae.
Biochem. J.
223:271-274[Medline].
|
| 19. |
Kopp, U.,
B. Wiedemann,
S. Lindquist, and S. Normark.
1993.
Sequences of wild-type and mutant ampD genes of Citrobacter freundii and Enterobacter cloacae.
Antimicrob. Agents Chemother.
37:224-228 |
| 20. |
Korfmann, G., and C. C. Sanders.
1989.
ampG is essential for high-level expression of AmpC beta-lactamase in Enterobacter cloacae.
Antimicrob. Agents Chemother.
33:1946-1951 |
| 21. |
Lindberg, F.,
S. Lindquist, and S. Normark.
1987.
Inactivation of the ampD gene causes semiconstitutive overproduction of the inducible Citrobacter freundii -lactamase.
J. Bacteriol.
169:1923-1928 |
| 22. |
Lindberg, F., and S. Normark.
1987.
Common mechanism of ampC -lactamase induction in enterobacteria: regulation of the cloned Enterobacter cloacae P99 -lactamase gene.
J. Bacteriol.
169:758-763 |
| 23. |
Lindberg, F.,
L. Westman, and S. Normark.
1985.
Regulatory components in Citrobacter freundii ampC -lactamase induction.
Proc. Natl. Acad. Sci. USA
82:4620-4624 |
| 24. |
Lindquist, S.,
F. Lindberg, and S. Normark.
1989.
Binding of the Citrobacter freundii AmpR regulator to a single DNA site provides both autoregulation and activation of the inducible ampC -lactamase gene.
J. Bacteriol.
171:3746-3753 |
| 25. |
Lindquist, S.,
K. Weston-Hafer,
H. Schmidt,
C. Pul,
G. Korfmann,
J. Erickson,
C. Sanders,
H. H. Martin, and S. Normark.
1993.
AmpG, a signal transducer in chromosomal -lactamase induction.
Mol. Microbiol.
9:703-715[CrossRef][Medline].
|
| 26. |
Livermore, D. M.
1995.
-Lactamases in laboratory and clinical resistance.
Clin. Microbiol. Rev.
8:557-584[Abstract].
|
| 27. |
Maejima, T.,
Y. Ohya,
S. Mitsuhashi, and M. Inoue.
1987.
Cloning and expression of the gene(s) for chromosome-mediated -lactamase production of Proteus vulgaris in Escherichia coli.
Plasmid
18:120-126[CrossRef][Medline].
|
| 28. | Marmur, J. 1961. A procedure for the isolation of deoxyribonucleic acid from micro-organisms. J. Mol. Biol. 3:208-218. |
| 29. |
Medeiros, A. A.
1997.
Evolution and dissemination of -lactamases accelerated by generations of -lactam antibiotics.
Clin. Infect. Dis.
24:19-45.
|
| 30. |
Minami, S.,
M. Inoue, and S. Mitsuhashi.
1980.
Purification and properties of a cephalosporinase from Enterobacter cloacae.
Antimicrob. Agents Chemother.
18:853-857 |
| 31. |
Minami, S.,
A. Yotsuji,
M. Inoue, and S. Mitsuhashi.
1980.
Induction of -lactamase by various -lactam antibiotics in Enterobacter cloacae.
Antimicrob. Agents Chemother.
18:382-385 |
| 32. |
Normark, S.
1995.
-Lactamase induction in gram-negative bacteria is intimately linked to peptidoglycan recycling.
Microb. Drug Resist.
1:111-114[Medline].
|
| 33. |
Normark, S.,
E. Bartowsky,
J. Erickson,
C. Jacobs,
F. Lindberg,
S. Lindquist,
K. W. Hafer, and M. Wikstrom.
1994.
Mechanisms of chromosomal -lactamase induction in gram-negative bacteria, p. 485-503.
In
J. M. Ghuysen, and R. Hakenbeck (ed.), Bacterial cell walls. Elsevier Science B. V., Amsterdam, The Netherlands.
|
| 34. |
Okamoto, R.,
T. Okubo, and M. Inoue.
1996.
Detection of genes regulating -lactamase production in Enterococcus faecalis and Staphylococcus aureus.
Antimicrob. Agents Chemother.
40:2550-2554[Abstract].
|
| 35. | Park, J. T. 1995. Why does Escherichia coli recycle its cell wall peptides? Mol. Microbiol. 17:421-426[Medline]. |
| 36. |
Saiki, R. K.,
D. H. Gelfand,
S. Stoffel,
S. J. Scharf,
R. Higuchi,
G. T. Horn,
K. B. Mullis, and H. A. Erlich.
1988.
Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.
Science
239:487-491 |
| 37. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 38. |
Sanders, C. C., and W. E. Sanders.
1979.
Emergence of resistance to cefamandole: possible role of cefoxitin-inducible -lactamases.
Antimicrob. Agents Chemother.
15:792-797 |
| 39. |
Sanger, F.,
S. Nicklen, and A. R. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467 |
| 40. | Stapleton, P., K. Shannon, and I. Phillips. 1995. DNA sequence differences of ampD mutants of Citrobacter freundii. Antimicrob. Agents Chemother. 39:2494-2498[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |